Clinical trials: Gastrointestinal Neoplasms, open to volunteers
Gastrointestinal Stromal Tumors
A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
The purpose of this study is to explore the safety of laparoscopic resection of 5cm or larger gastric gastrointestinal stromal tumors
- Trial name
- NCT05938309
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Fujian Medical University
Gastrointestinal Stromal Tumors
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
The goal of this Mesylate apatinib versus standard second-line TKI in the treatment of advanced gastrointestinal stromal tumors: a randomized, open, controlled, single-center clinical study is to explore the efficacy and safety…
- Trial name
- NCT05751733
- Testing
- Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Xiangya Hospital of Central South University
Neuroendocrine Tumors, Intestinal Neoplasms
Spanish Series of Patients Treated With the Radionuclide Lutetium177
This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of…
- Conditions
- Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
- Trial name
- SEPTRALU (NCT04949282)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 20 sites in Spain
- Volunteers
- 5,000 people
- Sponsor
- Sociedad Española de Medicina Nuclear e Imagen Molecular
Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma (ESCC) Patients as Postoperative Adjuvant Therapy.
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases, Gastrointestinal Neoplasms
- Trial name
- ALTER-E005 (NCT05252078)
- Testing
- Anlotinib hydrochloride, TQB2450
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Gastrointestinal Cancer
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
This study is a prospective single-arm phase II study to evaluate the efficacy and safety of Pemigatinib in the advanced gastrointestinal cancer with FGFR 1-3 alterations and failed standard therapy.
- Trial name
- NCT05651672
- Testing
- Pemigatinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cancer, Healthy
Collection and Distribution of Biospecimens for Novel Research Uses
iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with…
- Conditions
- Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases
- Trial name
- NCT03848962
- Where
- 2 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- iSpecimen Inc
Gastrointestinal Stromal Tumors, Minimal Residual Disease
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
So far, MRD assessment by liquid biopsy (ctDNA) has not been used to predict postoperative treatment efficacy and recurrence risk of GIST patients because of special disease characteristics and technological limitations.
- Trial name
- NCT05408897
- Testing
- liquid biopsy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University People's Hospital
Cachexia, Neoplasms
Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms
Muscle mass loss is a common adverse effect of cancer. Muscle mass loss occurs with or without reduction in body weight. Cancer cachexia (CC) is the involuntary loss of body weight of >5% within 6 months and it occurs in 50-80%…
- Conditions
- Cachexia, Neoplasms, Exercise, Metabolism
- Trial name
- PANACEA (NCT05307367)
- Testing
- Exercise training
- Where
- Denmark
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Gastrointestinal Neoplasms
Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms
The primary objective: association study of characteristics of tumoral microenvironment and immunity of digestive cancers with patients' overall survival (OS).
- Trial name
- HoMING (NCT04363983)
- Testing
- Blood sampling, Liver biopsy, Stool collect
- Where
- France
- Volunteers
- 6,300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Progression-free Survival, Gastrointestinal Stromal Tumor
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was relatively low, and the relapse-free survival rate was relatively low, which needed to be further improved.
- Conditions
- Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant
- Trial name
- ZJGIST-01 (NCT04933669)
- Testing
- Imatinib
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Circulating Tumor Cell, Gastrointestinal Cancer
EUS Guided HVA and PVA for Circulating Tumor DNA in Patients
The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" genomic diagnostics.
- Trial name
- NCT04782557
- Testing
- EUS-guided portal vein and hepatic vein aspiration
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong